Perfil oxidativo de la mujer menopáusica: papel de los estrógenos en la prevención y tratamiento de las enfermedades

Autores/as

  • Carlos Escalante Gómez Universidad de Costa Rica
  • Silvia Quesada Mora Universidad de Costa Rica
  • Fernando Zeledón Sánchez Universidad de Costa Rica

DOI:

https://doi.org/10.51481/amc.v51i4.490

Palabras clave:

estrés oxidativo, antioxidantes, menopausia, estrógenos

Resumen

El balance entre la producción de radicales libres de oxigeno y el nivel de enzimas antioxidantes es permanentemente regulado por la célula. Las enzimas antioxidantes son esenciales para las células aeróbicas, puesto que mantienen en niveles aceptables las concentraciones de especies químicas conocidas como radicales libres. Durante el climaterio o etapa perimenopáusica, el cuerpo y metabolismo de una mujer cambia de forma importante, y los mecanismos que regulan el estrés oxidativo no son la excepción. Los estrógenos, per se, son antioxidantes, y esto ha impulsado recientemente estudios sobre los efectos antioxidativos de los estrógenos, como un posible mecanismo preventivo para algunas enfermedades. En los últimos años se le ha brindado gran importancia al papel del estrés oxidativo en la génesis de algunas enfermedades como la ateroesclerosis y la enfermedad cardiovascular, algunos tipos de cánceres y la enfermedad de Alzheimer. Pareciera que los estrógenos sí modifican el equilibro oxidativo / antioxidativo in vivo, sin embargo aun se requieren más estudios para puntualizar el rol de estos como posibles tratamientos preventivos para la menopáusica.

 

 

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Blokhina O, Virolainen E, Fagerstedt KV. Antioxidants, oxidative damage and oxygen deprivation stress: a review. Ann Bot (Lond) 2003; 91: 179-194.

Angstadt C. Estructura de las macromoléculas. En: Bioquímica: libro de texto con aplicaciones clínicas. 4a ed. España: Reverté. 2004; 40 – 98.

Murray R. Bioenergética y el metabolismo de carbohidratos y lípidos. En: Bioquímica de Harper. 15va ed. México: El Manual Moderno, 2001; 88-149.

Young IS, Woodside JV. Antioxidants in health and disease. J Clin Pathol. 2001; 54: 176-186.

Scandalios JG. Oxidative stress: molecular perception and transduction of signals triggering antioxidant gene defensas. Braz J Med Re. 2005; 38: 995-1014.

Kyaw M, Yoshizumi M, Tsuchiya K, Izawa Y, Kanematsu Y, Tamaki T. Atheroprotective effects of antioxidants through inhibition of mitogen-activated protein kinases. Acta Pharmacol Sin. 2004; 25: 977-985.

Paolisso G, Esposito R, D’Alessio MA, Barbieri M. Primary and secondary prevention of atherosclerosis: is there a role for antioxidants? Diabetes Metab. 1999; 25: 298-306.

Willcox, J, Ash S, Catignani G. Antioxidants and prevention of chronic disease. Crit Rev Food Sci Nutr. 2004; 44: 275-295.

Tribble DL, Frank E. Dietary antioxidants, cancer and atherosclerotic heart disease. West J Med. 1994; 161:605-612.

Ebell MH. Efficacy of antioxidants in GI cancer prevention. Am Fam Physician. 2005; 71: 465-466.

Salaganik RL. The benefits and hazards of antioxidants: controlling apoptosis and other protective mechanisms in cancer patients and the human population. J Am Coll Nutr. 2001; 20(5 Suppl): 464S-475S.

Lamson DW, Brignall MS. Antioxidants and cancer, part 3: quercetin. Altern Med Rev. 2000; 5:304-329.

Christen Y. Oxidative stress in Alzheimer’s disease. Am J Clin Nutr. 2000; 71:621-629 S.

Smith, MA, Perry G, Richery PL. Oxidative damage in Alzheimer’s disease. Nature. 1996; 382: 120-121.

Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trail of high-dose supplementation with vitamins C and E and beta carotene for age related cataract and vision loss: AREDS report no.9. Arch Ophtalmol. 2001; 119:1439-1452.

Ehret A, Westendorp MO, Herr P, Debatin KM, Heeney JL, Frank R, et al. Resistance of chimpanzee T cells to human inmunodeficiency virus type 1 Tat-enhanced oxidative stress and apoptosis. J Virol. 1996; 70: 6502-6507.

Ortiz A, Vargas R, Muñoz G. Incidencia y mortalidad del cáncer en Costa Rica. Costa Rica: Kamelot Comunicación y Arte: 2005.

Siseles N. Información y formación para el manejo actual de la mujer en su climaterio. Buenos Aires: Ascune Hnos: 2005.

Stocker R, Keaney J. Role of oxidative modifications in atherosclerosis. Phsiol Rev. 2004; 84: 1381-1478.

Heinecke J. Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesis. Atherosclerosis. 1998; 141: 1-15.

Salonen T, Yla-Herttulal S, Yamamoto R. Autoantibodies against oxidized LDL and progression of carotid atherosclerosis. Lancet. 1992; 339:883-887.

Gey KF, Puska P, Jordan P, Moser UK. Inverse correlation between plasma vitamin E and mortality from isquemia Herat disease in crosscultural epidemiology. ACJN. 1991; 53: 326-334 S.

Stampfer MJ., Hennekens CH, Manson J, Colditz G, Rosner B, Willet W. Vitamin E consumption and risk of coronary disease in women. New Engl J Med. 1993; 328: 1444-1449.

Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ, et al. Randomized controlled trail of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996; 347: 781-786.

Yusuf S. Vitamin E supplementation and cardiovascular events in high risk patients. New Engl J Med. 2000; 354: 1917-1918.

Lee IM, Cook NR, Gaziano J, Gordon D, Ridker P, Manson J, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women’s Health Study: a randomized controlled trail. JAMA. 2005; 294: 56-65.

Wassmann K, Wassmann S, Nickenig G. Progesterone antagonizes the vasoprotective effect of estrogen on antioxidant enzyme expression and function. Circ Res. 2005; 97: 1046-1054.

Strehlow K, Rotter S, Wassmann S, Adam O, Grohe C, Laufs K. et al. Modulation of antioxidant enzime expression and function by estrogen. Circ Res. 2003; 93: 170-177.

Thibodeau P, Kachadourain R, Lemay R, Bission M, Day B, Paquette B. In vitro pro- and antioxidant properties of estrogen. J Steroid Biochem Mol Biol. 2002; 81: 227-236.

Gorodeski G. Update on cardiovascular disease in post-menopausal women. Best Pract Res Clin Obstet Gynaecol. 2002; 16: 329-355.

Clarkson TB. The new conundrum: do estrogens have any cardiovascular benefits? Int J Fertil Womens Med. 2002; 47: 61-68.

Signorelli S, Neri S, Sciacchitano S, DiPino L, Costa M, Marchese G. Behaviour of some indicators of oxidative stress in postmenopausal and fertile women. Maturitas. 2006; 53: 77-82.

Bednarek G, Tupikowski K, Bidzinska B, Bohdanowicz-Pawlak A, Antonowicz-Juchniewicz J, Kosouska B, et al. Serum lipid peroxides and total antioxidant status in postmenopausal women on hormone replacement therapy. Gynecol Endocinol. 2004; 19: 57-63.

Unfer T, Conterato M, da Silva J, Duarte M, Emanuelli T. Influence of hormonal replacement therapy on blood antioxidant enzymes in menopausal women. Clin Chem Acta. 2006; 369: 73-77.

Wen Y, Doyle M, Cooke T, Feely J. Effect of menopause on lowdensity lipoprotein oxidation: is oestrogen an important determinant? Maturitas. 2000; 34: 233-238.

Demirbag R, Yilmaz R, Erel O. The association of total antioxidant capacity with sex hormones. Scan Cardiovasc J. 2005; 36: 172-176.

Wells, G, Tugwell P, Shea B, Guyatt G, Peterson J, Zytaruk N. et al. Meta-analyses of therapies for postmenopausal osteoporosis. V. Metaanalysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev. 2002; 23:529-539.

Dick SE, DeWitt DE, Anawalt B. Postmenopausal hormone replacement therapy and mayor clinical outcomes: a focus on cardiovascular disease, osteoporosis, dementia and breast and endometrial neoplasia. Am J Manag Care. 2002; 8: 95- 104.

Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser N, et al. Estrogen plus progestin and the risk of coronary heart disease. New Engl J Med. 2003; 349: 523.

Sugioka K, Shimosegawa Y, Nakano M. Estrogens as natural antioxidants of membrane phospholipid peroxidation. FEBS lett 1987; 210: 37-39.

Ayres S, Abplanalp W, Liu J, Ravi T. Mechanisms involved in the protective effect of estradiol -17ß on lipid peroxidation and DNA damage. Am J Physiol. 1998; 274: E1002-E1008.

Subbiah MT, Kessel B, Agrawal M, Rajan R, Abplanalp W,

Rymaszewski Z. Antioxidant potential of specific estrogens on lipid peroxidation. J Clin Endocrinol Metab. 1993; 77: 1095-1097.

Taniguchi S, Yanase T, Kobayashi K, Takayanagi R, Haji M, Umeda F, et al. Catechol estrogens are more potent antioxidants than estrogens for the Cu(2+) catalyzed oxidation of low or high density lipoprotein: antioxidative effects of steroids on lipoproteins. Endocr J. 1994; 41:605-611.

Markides C, Roy D, Liehr G. Concentration dependence of prooxidant and antioxidant properties of catecholestrogens. Arch Biochem Biophys. 1998; 360: 105-112.

McManus J, McEneny J, Young IS, Thompson W. The effect of various oestrogens and progestogens on the susceptibility of low density lipoproteins to oxidation in vitro. Maturitas. 1996; 25: 125131.

Ayres SA, Tang M, Subbiah MT. Estradiol 17β as an antioxidant: some distinct features when compared with common fat-soluble antioxidants. J Lab Clin Med. 1996; 128: 367-375.

Arteaga E, Rojas A, Villaseca P, Bianchi M, Arteaga A, Duran D. In vitro effect of estradiol, progesterone, testosterone and of combined estradiol/progestins on low density lipoprotein oxidation in postmenopausal women. Menopause. 1998; 5: 16-23.

Ke R, Todd D, Ahokas R. Effect of short-term hormone therapy on oxidative stress and endothelial function in African American and Caucassian postmenopausal women. Fertil Steril. 2003; 79: 11181122.

McManus J, McEneny, Thompson W, Young IS. The effect of hormone replacement therapy on the oxidation of low density lipoprotein in postmenopausal women. Atherosclerosis. 1997; 135: 73-81.

Inal M, Sunal E, Kanvak G, Zeytinoglu S. Effects of postmenopausal hormone replacement and alpha-tocopherol on the lipid profiles and antioxidant status. Clin Chem Acta. 1998; 268: 21-29.

Ozden S, Dildar K, Hakan Y, Guilzar K. The effects of hormone replacement therapy on lipid peroxidation and antioxidant status. Maturitas. 2001; 38: 165-170.

Naziroglu M, Simsek M, Simsek H, Aydilek N, Ozcan Z, Artilgan R. The effects of hormone replacement therapy combined with vitamins C and E on antioxidant levels and lipid profiles in postmenopausal women with Type 2 diabetes. Clin Chim Acta. 2004; 344: 63-71.

Wen Y, Doyle M, Norris L, Sinnott M, Cooke T, Harrison R, et al. Combined oestrogen-progesteron replacement therapy does not inhibit low-density lipoprotein oxidation in postmenopausal women. Br J Clin Phamacol. 1999; 47: 315-321

Bureau I, Anderson R, Arnaud J, Raysifuier Y, Favier A, Roussel A. Trace mineral status in post menopausal women: impact of hormonal replacement therapy. J Trace Elem Med Biol. 2002; 16: 9-13.

Bureau I, Laporte F, Favier M, Faure H, Fields M, Favier A. et al. No antioxidant effect of combined HRT on LDL Oxidability and Oxidative stress biomarkers in treated post menopausal women. J Am Coll Nutr. 2002; 21: 333-338.

Halliwell B, Grootveld M, The measurement of free radical reactions in humans. FEBS lett 1987; 213 9-14.

Kaur I, Geetha T. Screening methods for antioxidants- a review. Mini Rev Med Chem. 2006; 6: 305-312.

Halliwell B, Clement MV, Long LH. Hydrogen peroxide in the human body. FEBS Lett 2000; 486: 10-13

Long LH, Evans PJ, Haliwell B. Hydrogen peroxide in human urine: implications for antioxidant defense and redox regulation. Biochem Biophys Res Commun. 1999; 262: 605-609.

Morrow JD, Hill KE, Burk RE. A series of prostaglandin F2-like compunds are produced in vivo in humans by non-cyclooxygenase, free radical-catalyed mechanism. Proc Natl Acad Sci USA. 1999; 87: 9383-9387.

Yagi K. Simple assay for the level of total lipid peroxides in serum or plasma. Methods Mol Biol. 1998; 108: 101-106.

Armstrong D, Browne R. The analysis of free radicals, lipid peroxides, antioxidant enzymes and compounds to oxidative stress as applied to the clinical chemistry laboratory. Adv Exp Med Biol. 1994; 366: 4358.

Stadtman ER, Oliver CN. Metal-catalyzed oxidation of proteins. Physiological consequences. J Biol Chem. 1991; 266: 2005-2008.

Beckman KB, Arnes B. Oxidative decay of DNA. J Biol Chem. 1997; 272: 19633-19636.

Kampa M, Nistikaki A. Tsaousis V. A new automated method for the determination of the total antioxidant capacity (TAC) of human plasma, based on the crocin bleachin assay. BMC Clinical Pathology.

; 2: 3-18.

Descargas

Publicado

2009-09-17

Cómo citar

Escalante Gómez, C., Quesada Mora, S., & Zeledón Sánchez, F. (2009). Perfil oxidativo de la mujer menopáusica: papel de los estrógenos en la prevención y tratamiento de las enfermedades. Acta Médica Costarricense, 51(4), 206–212. https://doi.org/10.51481/amc.v51i4.490